Literature DB >> 28137828

Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome.

Antiopi Varelias1,2, Kate L Ormerod3, Mark D Bunting1, Motoko Koyama1,2, Kate H Gartlan1,2, Rachel D Kuns1, Nancy Lachner3, Kelly R Locke1, Chun Y Lim1, Andrea S Henden1, Ping Zhang1, Andrew D Clouston4, Sumaira Z Hasnain5, Michael A McGuckin5, Bruce R Blazar6, Kelli P A MacDonald1, Philip Hugenholtz3, Geoffrey R Hill1,2,7.   

Abstract

Donor T-cell-derived interleukin-17A (IL-17A) can mediate late immunopathology in graft-versus-host disease (GVHD), however protective roles remain unclear. Using multiple cytokine and cytokine receptor subunit knockout mice, we demonstrate that stem cell transplant recipients lacking the ability to generate or signal IL-17 develop intestinal hyper-acute GVHD. This protective effect is restricted to the molecular interaction of IL-17A and/or IL-17F with the IL-17 receptor A/C (IL-17RA/C). The protection from GVHD afforded by IL-17A required secretion from, and signaling in, both hematopoietic and nonhematopoietic host tissue. Given the intestinal-specificity of the disease in these animals, we cohoused wild-type (WT) with IL-17RA and IL-17RC-deficient mice, which dramatically enhanced the susceptibility of WT mice to acute GVHD. Furthermore, the gut microbiome of WT mice shifted toward that of the IL-17RA/C mice during cohousing prior to transplant, confirming that an IL-17-sensitive gut microbiota controls susceptibility to acute GVHD. Finally, induced IL-17A depletion peritransplant also enhanced acute GVHD, consistent with an additional protective role for this cytokine independent of effects on dysbiosis.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28137828      PMCID: PMC5391622          DOI: 10.1182/blood-2016-08-732628

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

Review 1.  The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation.

Authors:  G R Hill; J L Ferrara
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

2.  Intestinal Interleukin-17 Receptor Signaling Mediates Reciprocal Control of the Gut Microbiota and Autoimmune Inflammation.

Authors:  Pawan Kumar; Leticia Monin; Patricia Castillo; Waleed Elsegeiny; William Horne; Taylor Eddens; Amit Vikram; Misty Good; Alexi A Schoenborn; Kyle Bibby; Ronald C Montelaro; Dennis W Metzger; Ajay S Gulati; Jay K Kolls
Journal:  Immunity       Date:  2016-03-15       Impact factor: 31.745

3.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.

Authors:  G R Hill; J M Crawford; K R Cooke; Y S Brinson; L Pan; J L Ferrara
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

Review 4.  Innate IL-17-producing cells: the sentinels of the immune system.

Authors:  Daniel J Cua; Cristina M Tato
Journal:  Nat Rev Immunol       Date:  2010-06-18       Impact factor: 53.106

Review 5.  The IL-17 differentiation pathway and its role in transplant outcome.

Authors:  Jonathan S Serody; Geoffrey R Hill
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

6.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Authors:  Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

7.  Enteral metronidazole for the prevention of graft versus host disease in pediatric marrow transplant recipients: results of a pilot study.

Authors:  S L Guthery; J E Heubi; A Filipovich
Journal:  Bone Marrow Transplant       Date:  2004-06       Impact factor: 5.483

8.  IL-17 contributes to CD4-mediated graft-versus-host disease.

Authors:  Lucy W Kappel; Gabrielle L Goldberg; Christopher G King; David Y Suh; Odette M Smith; Cassandra Ligh; Amanda M Holland; Jeremy Grubin; Nicholas M Mark; Chen Liu; Yoichiro Iwakura; Glenn Heller; Marcel R M van den Brink
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

9.  Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells.

Authors:  Rémi J Creusot; Shahriar S Yaghoubi; Pearl Chang; Justine Chia; Christopher H Contag; Sanjiv S Gambhir; C Garrison Fathman
Journal:  Blood       Date:  2009-04-10       Impact factor: 22.113

10.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

View more
  34 in total

Review 1.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  Recipient mucosal-associated invariant T cells control GVHD within the colon.

Authors:  Antiopi Varelias; Mark D Bunting; Kate L Ormerod; Motoko Koyama; Stuart D Olver; Jasmin Straube; Rachel D Kuns; Renee J Robb; Andrea S Henden; Leanne Cooper; Nancy Lachner; Kate H Gartlan; Olivier Lantz; Lars Kjer-Nielsen; Jeffrey Yw Mak; David P Fairlie; Andrew D Clouston; James McCluskey; Jamie Rossjohn; Steven W Lane; Philip Hugenholtz; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

3.  ST2/MyD88 Deficiency Protects Mice against Acute Graft-versus-Host Disease and Spares Regulatory T Cells.

Authors:  Brad Griesenauer; Hua Jiang; Jinfeng Yang; Jilu Zhang; Abdulraouf M Ramadan; Jane Egbosiuba; Khaled Campa; Sophie Paczesny
Journal:  J Immunol       Date:  2019-04-12       Impact factor: 5.422

Review 4.  The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease.

Authors:  Motoko Koyama; Geoffrey R Hill
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

5.  A critical role for donor-derived IL-22 in cutaneous chronic GVHD.

Authors:  Kate H Gartlan; Hemamalini Bommiasamy; Katelyn Paz; Andrew N Wilkinson; Mary Owen; Dawn K Reichenbach; Tatjana Banovic; Kimberly Wehner; Faith Buchanan; Antiopi Varelias; Rachel D Kuns; Karshing Chang; Yuri Fedoriw; Thomas Shea; James Coghill; Michael Zaiken; Maximilian W Plank; Paul S Foster; Andrew D Clouston; Bruce R Blazar; Jonathan S Serody; Geoffrey R Hill
Journal:  Am J Transplant       Date:  2017-10-24       Impact factor: 8.086

Review 6.  Gut Microbiota and IL-17A: Physiological and Pathological Responses.

Authors:  Banafsheh Douzandeh-Mobarrez; Ashraf Kariminik
Journal:  Probiotics Antimicrob Proteins       Date:  2019-03       Impact factor: 4.609

Review 7.  The gut microbiota and graft-versus-host disease.

Authors:  David N Fredricks
Journal:  J Clin Invest       Date:  2019-05-01       Impact factor: 14.808

Review 8.  Gut microbiota injury in allogeneic haematopoietic stem cell transplantation.

Authors:  Yusuke Shono; Marcel R M van den Brink
Journal:  Nat Rev Cancer       Date:  2018-02-16       Impact factor: 60.716

Review 9.  Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis.

Authors:  James Lm Ferrara; Christopher M Smith; Julia Sheets; Pavan Reddy; Jonathan S Serody
Journal:  J Clin Invest       Date:  2017-06-05       Impact factor: 14.808

10.  MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota.

Authors:  Motoko Koyama; Pamela Mukhopadhyay; Iona S Schuster; Andrea S Henden; Jan Hülsdünker; Antiopi Varelias; Marie Vetizou; Rachel D Kuns; Renee J Robb; Ping Zhang; Bruce R Blazar; Ranjeny Thomas; Jakob Begun; Nicola Waddell; Giorgio Trinchieri; Robert Zeiser; Andrew D Clouston; Mariapia A Degli-Esposti; Geoffrey R Hill
Journal:  Immunity       Date:  2019-09-18       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.